- Investing Ideas
- Taiwanese Pharmaceuticals & Biotech Top Stock Picks from Analysts
Taiwanese Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$159.4b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$102.50
7D
-7.7%
1Y
-35.7%
Lotus Pharmaceutical
Market Cap: NT$48.2b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$183.50
7D
-5.2%
1Y
-5.4%
Oneness Biotech
Market Cap: NT$22.5b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$46.90
7D
3.2%
1Y
-33.3%
TaiMed Biologics
Market Cap: NT$16.8b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$61.60
7D
1.0%
1Y
-22.4%
Medigen Vaccine Biologics
Market Cap: NT$16.6b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$50.40
7D
-2.9%
1Y
27.3%
EirGenix
Market Cap: NT$14.8b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$48.70
7D
-3.9%
1Y
-19.8%
Foresee Pharmaceuticals
Market Cap: NT$12.5b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$79.20
7D
-0.5%
1Y
1.7%